{"podcast":{"title":"Primary Care Update","slug":"primary-care-update-1000928","podcast_index_feed_id":1000928,"rss_url":"https://anchor.fm/s/5693a5c/podcast/rss","website_url":"https://podcasters.spotify.com/pod/show/primary-care-update","image_url":"https://d3t3ozftmdmh3i.cloudfront.net/production/podcast_uploaded_nologo/807823/807823-1535146710716-0fbae5650ccb6.jpg","author":"Mark Ebell","episode_count":207,"summary":"Four healthily skeptical primary care physicians discuss the latest in primary care medicine. Join Essential Evidence Editor Mark Ebell MD, Rush University's Kate Rowland MD, MSU Professor of Medicine Gary Ferenchick MD, and POEMs co-founder Henry Barry MD, MS for this fast-paced weekly update on evidence-based primary care.","last_synced_at":null,"page_url":"https://stenobird.com/podcast/primary-care-update-1000928"},"episode":{"title":"Episode 193: Intensive BP lowering, elinzanetant for VMS, HTN in pregnancy and prostate CA screening","slug":"episode-193-intensive-bp-lowering-elinzanetant-for-vms-htn-in-pregnancy-and-prostate-ca-screening","published_at":"2025-11-12T00:10:07+00:00","page_url":"https://stenobird.com/podcast/primary-care-update-1000928/episode-193-intensive-bp-lowering-elinzanetant-for-vms-htn-in-pregnancy-and-prostate-ca-screening","show_page_url":"https://stenobird.com/podcast/primary-care-update-1000928","url":"https://podcasters.spotify.com/pod/show/primary-care-update/episodes/Episode-193-Intensive-BP-lowering--elinzanetant-for-VMS--HTN-in-pregnancy-and-prostate-CA-screening-e3arcdb","audio_url":"https://anchor.fm/s/5693a5c/podcast/play/111046507/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2025-10-11%2Fc5045e3a-d847-7392-d117-2688afd9d4da.mp3","summary":"Primary care physicians Gary Ferenchick, Kate Rowland, Henry Barry and Mark Ebell want you to know about 4 new studies: the best choice of pharmacotherapy in hypertensive disorders of pregnancy, benefits and harms of intensive BP lowering, elinzanetant for therapy-induced vasomotor symptoms in women with breast cancer, and 23 year follow up of the European Prostate Cancer Screening Trial. Plus a confusing quiz question (thanks Gary!). Links Essential Evidence Plus: www.essentialevidenceplus.com HTN in pregnancy: https://pubmed.ncbi.nlm.nih.gov/40216176/ Intensive BP lowering: https://pubmed.ncbi.nlm.nih.gov/40902616/ Elinzanetant for vasomotor symptoms in patients taking tamoxifen or anastrozole: https://pubmed.ncbi.nlm.nih.gov/40454634/ 23 year follow-up of large European prostate cancer study: https://pubmed.ncbi.nlm.nih.gov/41160819/","meta_description":"Primary care physicians Gary Ferenchick, Kate Rowland, Henry Barry and Mark Ebell want you to know about 4 new studies: the best choice of pharmacotherapy…","key_points":[],"chapters":[],"topics":[],"duration_seconds":2292,"processing_state":"not_requested","actions":[{"name":"request_transcript","method":"POST","url":"https://stenobird.com/v1/public/podcasts/primary-care-update-1000928/episodes/episode-193-intensive-bp-lowering-elinzanetant-for-vms-htn-in-pregnancy-and-prostate-ca-screening/transcription-requests","description":"Idempotently request low-priority transcript generation for this episode."},{"name":"read_markdown","method":"GET","url":"https://stenobird.com/podcast/primary-care-update-1000928/episode-193-intensive-bp-lowering-elinzanetant-for-vms-htn-in-pregnancy-and-prostate-ca-screening.md","description":"Read the agent-friendly Markdown representation of this episode resource."}]}}